State Of Wyoming Arcus Biosciences, Inc. Transaction History

State Of Wyoming

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$15.96 - $23.15 $12,831 - $18,612	804 Added 34.96%	3,104 $56,000
Q4 2022 Feb 14, 2023	BUY	$19.7 - $35.71 $45,310 - $82,133	2,300 New	2,300 $47,000
Q2 2022 Aug 15, 2022	BUY	$17.23 - $37.73 $13,577 - $29,731	788 Added 95.75%	1,611 $41,000
Q1 2022 May 13, 2022	BUY	$28.92 - $41.83 $23,801 - $34,426	823 New	823 $26,000
Q2 2021 Feb 11, 2022	SELL	$22.75 - $35.77 $68 - $107	-3 Closed	0 $0
Q1 2021 Feb 08, 2022	BUY	$26.16 - $41.39 $78 - $124	3 New	3 $0

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.